Compare Incyte Corporation (INCY) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tencent Music Entertainment Group - ADR — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Tencent Music Entertainment Group - ADR trades at $8.46 (market cap $16.09B). The key difference: Incyte Corporation is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TME | |
|---|---|---|
Market Cap | $24.54B | $16.09B |
Sector | Health | Media |
52-Week High | $129.93 | $26.36 |
52-Week Low | $81.61 | $8.16 |
Enterprise Value | $20.04B | $14.05B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
TME stock trades at $8.45, down 14.65% in the last session amid mixed earnings results. The company reported Q2 2026 revenue growth of 6% year-over-year but faces slowing operational growth and competitive pressures. Valuation metrics appear reasonable with a P/E of 10.29 and P/S of 2.71, while profitability remains strong with a net income margin of 26.28%. Technical indicators signal a bearish trend, with the stock near key support levels.
The outlook is cautious; while TME's fundamentals are solid with robust cash flow and profitability, near-term headwinds from competition and market sentiment pose risks. Analyst consensus is divided, with 46% buy ratings but 50% hold, reflecting uncertainty over growth sustainability. Investors should weigh the attractive valuation against execution risks in a challenging environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
